Login to Your Account

CARs Run Over Leukemia Cells

Chimeric Immune Cells Lead To Advanced Leukemia Remissions

By Anette Breindl

Friday, August 12, 2011
Dendreon's Corp's Provenge (sipuleucel-T), the first FDA-approved cancer immunotherapy, may have had an underwhelming welcome from the medical community. (See BioWorld Today, Aug. 5, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription